Exploring and Expanding the Fatty-Acid-Binding Protein Superfamily in Fasciola Species by Morphew, Russell M et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exploring and Expanding the Fatty-Acid-Binding Protein
Superfamily in Fasciola Species
Citation for published version:
Morphew, RM, Wilkinson, TJ, Mackintosh, N, Jahndel, V, Paterson, S, McVeigh, P, Abbas Abidi, SM,
Saifullah, K, Raman, M & Ravikumar, G 2016, 'Exploring and Expanding the Fatty-Acid-Binding Protein
Superfamily in Fasciola Species' Journal Of Proteome Research, vol 15, no. 9, pp. 3308-3321. DOI:
10.1021/acs.jproteome.6b00331
Digital Object Identifier (DOI):
10.1021/acs.jproteome.6b00331
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal Of Proteome Research
Publisher Rights Statement:
This is an open access article published under a Creative Commons Attribution (CC-BY) License, which permits
unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 30. Jun. 2018
Exploring and Expanding the Fatty-Acid-Binding Protein Superfamily
in Fasciola Species
Russell M. Morphew,*,† Toby J. Wilkinson,† Neil Mackintosh,† Veronika Jahndel,‡ Steve Paterson,§
Paul McVeigh,∥ Syed. M. Abbas Abidi,⊥ Khalid Saifullah,⊥ Muthusamy Raman,#
Gopalakrishnan Ravikumar,# James LaCourse,▽ Aaron Maule,∥ and Peter M. Brophy†
†Aberystwyth University, Institute of Biological, Environmental and Rural Sciences, Aberystwyth SY23 3DA, United Kingdom
‡University of Leipzig, Institute of Biochemistry, D-04103 Leipzig, Germany
§University of Liverpool, School of Biological Sciences, Liverpool L69 7ZB, United Kingdom
∥Queen’s University Belfast, School of Biological Sciences, Belfast BT7 1NN, United Kingdom
⊥Aligarh Muslim University, Aligarh, Uttar Pradesh 202002, India
#Tamil Nadu Veterinary and Animal Sciences University, Chennai 600-051, India
▽Liverpool School of Tropical Medicine, Liverpool L3 5QA, United Kingdom
*S Supporting Information
ABSTRACT: The liver ﬂukes Fasciola hepatica and F. gigantica infect
livestock worldwide and threaten food security with climate change and
problematic control measures spreading disease. Fascioliasis is also a
foodborne disease with up to 17 million humans infected. In the absence
of vaccines, treatment depends on triclabendazole (TCBZ), and overuse
has led to widespread resistance, compromising future TCBZ control.
Reductionist biology from many laboratories has predicted new
therapeutic targets. To this end, the fatty-acid-binding protein (FABP)
superfamily has proposed multifunctional roles, including functions
intersecting vaccine and drug therapy, such as immune modulation and
anthelmintic sequestration. Research is hindered by a lack of under-
standing of the full FABP superfamily complement. Although discovery
studies predicted FABPs as promising vaccine candidates, it is unclear if
uncharacterized FABPs are more relevant for vaccine formulations. We
have coupled genome, transcriptome, and EST data mining with proteomics and phylogenetics to reveal a liver ﬂuke FABP
superfamily of seven clades: previously identiﬁed clades I−III and newly identiﬁed clades IV−VII. All new clade FABPs were
analyzed using bioinformatics and cloned from both liver ﬂukes. The extended FABP data set will provide new study tools to
research the role of FABPs in parasite biology and as therapy targets.
KEYWORDS: Fasciola hepatica, F. gigantica, proteomics, diagnosis, gene characterization
■ INTRODUCTION
The trematode liver ﬂukes, Fasciola hepatica and F. gigantica, are
the causative agents of fasciolosis, a foodborne zoonotic disease
aﬀecting grazing animals and humans worldwide. Liver ﬂuke
causes economic losses of over US$ 3 billion worldwide per
annum to livestock via mortality, reduction in host fecundity,
susceptibility to other infections, decrease in meat, milk, and
wool production and condemnation of livers.1 Liver ﬂuke disease
of livestock is increasing worldwide,2 with a number of potential
contributing factors: climate change (warmer winters and wetter
summers supporting larger intermediate mud snail host
populations); fragmented disease management (only treating
sheep not cattle and limiting veterinary interaction); encourage-
ment of wetlands; livestock movement; or failure/resistance of
chemical control treatments in the absence of commercial
vaccines.3,4 Fasciolosis is also a re-emerging human disease with
estimates of between 2.4 and 17 million people infected
worldwide.5−7 Furthermore, worldwide livestock movement is
providing new opportunities for the introduction of pathogenic
isolates.4
Control of liver ﬂuke is currently via anthelmintics. The
benzimidazole (BZM)-derivative, triclabendazole (TCBZ), is
the drug most extensively used against Fasciola. Unlike other
fasciolicides, TCBZ shows activity against both juvenile ﬂukes,
which are responsible for the damage to the liver of acute
fasciolosis, and the mature ﬂukes, which cause the debilitation of
chronic fasciolosis.8 However, TCBZ-resistant liver ﬂuke are
increasing throughout Europe and Australia, compromising
control eﬀorts.9−12 Following end of patent protection, generic
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forms of TCBZ will likely lead to wider application, potential
misuse and exacerbation of the spread of resistance.
The mode of action of TCBZ at the molecular level has yet to
be resolved. Laboratories report a variety of biological eﬀects of
TCBZ on liver ﬂuke (for reviews see refs 9 and 13). As well as
increased eﬄux,14 enhanced biotransformation and metabolism
of TCBZ has also been hypothesized to play a major role in
detoxiﬁcation and resistance. Anthelmintic resistance can arise
from eﬃcient detoxiﬁcation via Phase II and Phase III
conjugation, sequestration, and eﬄux mechanisms. To this
end, a type I fatty-acid-binding protein (FABP), Fh15 protein,
with sequestration potential is signiﬁcantly upregulated on
TCBZ exposure in resistant adult liver ﬂuke,15 and an FABP from
Schistosoma japonicum has been reported to play a role in
Praziquantel drug binding.16 Moreover, increased expression of
FABP mRNA occurs in drug-resistant strains of Anopheles
gambiae during permethrin insecticide exposure.17 Thus,
increased expression of FABP may be a generic invertebrate
response to drug challenge and a potential resistance marker.
The soluble super family of FABPs are small (14,15 kDa)
proteins that bind or sequestrate hydrophobic ligands such as
anthelmintics.16 The precise function of each FABP type has
remained imperfectly understood since subspecialization of
functions was suggested. At least nine distinct types of
cytoplasmic FABPs have been identiﬁed in mammals, each
showing a characteristic pattern of tissue distribution.18 FABPs
isolated from the same tissue of diﬀerent vertebrate species show
sequence identities of 70% and higher, whereas FABPs isolated
from diﬀerent tissues of a single species have sequence similarity
as low as 20%. However, their tertiary structure is remarkably
conserved, consisting of 10 antiparallel β-strands comprising a β-
barrel (containing conserved amino acid residues that are
involved in ligand binding) and a helix-turn-helix cap.16
Importantly, for vaccine candidature and drug sequestration,
FABP is also an abundant component of the soluble tegumental
proteome of adult liver ﬂuke.19,20 Vaccination against liver ﬂuke
remains in the research stage.21,22 Previous studies have placed
cytosolic FABPs among themajor potential vaccine candidates.23
Vaccine trials suggest that both native and recombinant F.
hepatica FABPs induce signiﬁcant levels of protection in diﬀerent
animal models against infection with F. hepatica and cross-
protection against S. mansoni and S. bovis with antiﬂuke,
antifecundity, and antipathology eﬀects.23
The recent discovery of FABPs in the cargo of exosome-like
vesicles released from adult F. hepatica,24 suggests new roles for
parasite FABPs within host cells. In support of this hypothesis, in
vitro assays demonstrate that FABP I (Fh12) alters the behavior
of monocyte-derived macrophages, with increased arginase
expression/activity and an increase in Chitinase-3-like protein.25
FABP I also down-regulated nitric oxide production and the
expression of nitric oxide synthase in interacting cells, exhibiting
a potent anti-inﬂammatory eﬀect in inducing the production of
alternatively activated macrophages.25 Furthermore, FABP I has
been shown to suppress inﬂammatory cytokines in a model of
septic shock potentially delivering its eﬀect via binding to CD14
coreceptors.26
Despite growing evidence supporting the importance of
FABPs for the establishment of liver ﬂuke in the vertebrate host,
our knowledge of the superfamily complement is fragmented
even with many reductionist studies. We report the mining of the
genome, transcriptomic and EST data sets, supplemented with
proteomics and phylogenetics, to systematically reveal the
complexity and novelty within the liver ﬂuke FABP superfamily.
Furthermore, we have identiﬁed which of these FABPs are
recognized by the immune system for further vaccine discovery.
■ EXPERIMENTAL PROCEDURES
Fluke Collection and Cultures
Adult F. hepatica were recovered from naturally infected ovine
livers immediately postslaughter from a local abattoir in Mid-
Wales, U.K. Fluke were washed several times in PBS at 37 °C to
remove host material by regurgitation of gut contents, as
previously described.27 Adult ﬂukes were transported to the
laboratory and maintained in Fasciola saline (FS; Dulbecco’s
modiﬁed Eagle’s medium (DMEM) [w/o NaHPO3 and PO4]
plus 2.2 mMCa [C2H3O2], 2.7 mMMgSO4, 61.1 mM glucose, 1
μM serotonin, 5 μg mL−1 gentamycin, 15 mM N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES), pH
7.4) at 37 °C for 2 h. Metacercariae were purchased from
Ridgeway Research and excysted following the physiological
method outlined by Dixon28,29 and previously described.30
Cytosol Preparations and 2DE
F. hepatica extracts were obtained by homogenization of frozen
ﬂuke at 4 °C in lysis buﬀer containing 20 mM potassium
phosphate, pH 7.4, 0.1% (v/v) Triton-X100, and protease
inhibitors (Roche, Complete-Mini, EDTA-free). After homog-
enization, samples were centrifuged at 100 000g for 1 h at 4 °C,
and the supernatant was termed the cytosolic fraction. Cytosolic
protein extracts were precipitated with an equal volume of ice-
cold 20% TCA in acetone (w/v) and washed twice in ice-cold
acetone before solubilization into isoelectric focusing buﬀer (IEF
buﬀer) consisting of 8 M urea, 2% w/v CHAPS, 33 mM DTT,
and 0.5% carrier ampholytes v/v (Biolyte 3-10, Bio-Rad) as
previously described.31 For preliminary 2DE, a total of 100 μg
was passively in-gel rehydrated for 16 h and isoelectrically
focused on 7 cm linear pH 3−10 IPG strips (BioRad) for 10 000
Vh. For analytical 2DE a total of 500 μg of each replicate sample
was passively in-gel rehydrated for 16 h and isoelectrically
focused on 17 cm pH 4.7 to 5.9 or 7−10 IPG strips (BioRad) to
60 000 Vh. All IEF was conducted on a Protean IEF Cell (Bio-
Rad).
After focusing, strips were equilibrated for 15 min in reducing
equilibration buﬀer (30% v/v glycerol, 6 M urea, 1% DTT),
followed by 15 min in alkylating equilibration buﬀer (30% v/v
glycerol, 6 M urea, 4% iodoacetamide). IPG strips were run upon
SDS-PAGE (14% acrylamide) using the Protean II xi 2D Cell
(BioRad) for 17 cm or PROTEAN Mini (Bio-Rad, U.K.) for 7
cm 2DE. Gels were Coomassie blue stained (Phastgel Blue R,
Amersham Biosciences) and scanned on a GS-800 calibrated
densitometer (BioRad).
Gel image quantitative diﬀerences between protein spots were
analyzed via Progenesis PG220 software, version 2006 (Non-
linear Dynamics). Spots were manually detected on gels with
normalization performed using total spot volume multiplied by
100. Quantitative analysis was based on average gels created from
four biological replicates.
Protein Identiﬁcation
Protein spots were manually excised and tryptically digested and
prepared for mass spectrometry as previously described.32,33
Tandemmass spectrometry (MS/MS) was performed according
to the method of Moxon et al.,34 followed by data processing for
database searching. Samples prepared for liquid chromatog-
raphy−tandem mass spectrometry (LC−MS/MS) were ana-
lyzed using electrospray ionization (ESI), as previously
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reported.34 Peptide mixtures from trypsin-digested gel spots
were separated using a LCPackings Ultimate nano-HPLC
System. Sample injection was via an LC Packings Famos
autosampler, and the loading solvent was 0.1% formic acid. The
precolumn used was a LCPackings C18 PepMap 100, 5 mm, 100
Å, and the nano HPLC column was a LC Packings PepMap C18,
3 mm, 100 Å. The solvent system was: solvent A (2% ACN with
0.1% formic acid) and solvent B (80% ACN with 0.1% formic
acid). The LC ﬂow rate was 0.2 μL/min with a gradient
employed using 5% solvent A to 100% solvent B in 1 h. The
HPLC eluent was sprayed into the nano-ES source of a Waters
Q-TOFμMS via a New Objective Pico-Tip emitter. The MS was
operated in positive ion mode, and multiply charged ions were
detected using a data-directed MS/MS experiment. Collision-
induced dissociation (CID) MS/MSmass spectra were recorded
over the mass range m/z 80−1400 Da with scan time 1 s.
MassLynx v 3.5 (Waters, U.K.) ProteinLynx suite of tools was
used to process raw fragmentation spectra. Each spectrum was
combined and smoothed twice using the Savitzky−Golay
method at ±3 channels with background noise subtracted at
polynomial order 15 and 10% below curve. Monoisotopic peaks
were centered at 80% centroid setting. Sequest compatible (.dta)
ﬁle peak mass lists for each spectrum were exported, and spectra
common to each 2DE spot were merged into a single MASCOT
generic format (.mgf) ﬁle using the online Peak List Conversion
Utility available at www.proteomecommons.org. Merged ﬁles
were submitted to a MASCOT MS/MS ions search within a
locally installed Mascot server (www.matrixscience.com) to
search an “in-house” database constructed from 6260 (858 763
residues) F. hepatica EST sequences were downloaded and
translated from the Sanger Institute (ftp://ftp.sanger.ac.uk/pub/
project/pathogens/Fasciola/hepatica/ESTs/). Search parame-
ters were as described in Morphew et al.33
Western Blotting
Western blotting samples were prepared and separated according
to the method described above. Proteins were transferred to
HybondTM-C Extra nitrocellulose membrane (GE Healthcare)
using a Trans-blot Cell (Bio-Rad) at 20 V overnight. Transfer
was carried out in 192 mM glycine (Sigma), 25 mM Tris base,
and 20% (v/v) methanol according to the method of Towbin et
al.35 The membrane was stained for 1 min with 0.1% (w/v)
amido black 10B (Naphthol Blue Rack, Sigma) in 10% (v/v)
acetic acid and 25% (v/v) isopropanol and destained in 10% (v/
v) acetic acid and 25% (v/v) isopropanol to evaluate transfer
eﬃciency.
NC membranes were blocked in TTBS (0.1 M Tris base, pH
7.5, 0.9% (w/v) NaCl, 1% (v/v) TweenR 20 (Acros)) containing
5% (w/v) skimmed milk powder for a minimum of 4 h.
Membranes were then washed in TTBS for 10 min before being
incubated for 1 h with the primary antibody diluted at 1:5000 in
TTBS containing 1% (w/v) skimmed milk powder. In all
Western blots pooled, bovine whole sera from Fasciola hepatica-
challenged and naiv̈e cattle were used as previously described.36
Membranes were washed three times for 5 min in TBS (0.1 M
Tris base, pH 7.5, 0.9% (w/v) NaCl, 1% (v/v)) to remove
residual primary antibody and incubated for 1 h with antibovine
IgG (whole molecule) conjugated to alkaline phosphatase (AKP,
Sigma) diluted at 1:30 000 or antibovine IgM (whole molecule)
conjugated to AKP (Novus Biologicals) diluted at 1:1000 both in
TTBS containing 1% (w/v) skimmed milk powder. The
membranes were again washed three times for 5 min in TBS.
Visualization of the resulting immunocomplexes was achieved by
developing the membranes in 5-bromo-4-chloro-3-indolyl
phosphate (BCIP; Sigma) and nitro blue tetrazolium (NBT;
BDH, VWR Life Sciences) according to the manufacturer’s
instruction.
Bioinformatics: Transcripts and Phylogenetics
All sequence alignments were carried out using ClustalW
multiple alignment37 via BioEdit Version 7.0.9.0 (6/27/07).38
Previously published FABP sequences from both Fasciola species
were retrieved from the Genbank database (http://www.ncbi.
nlm.nih.gov/) and aligned with ESTs and transcripts from
available sources39(ftp://ftp.sanger.ac.uk/pub/project/
pathogens/Fasciola/hepatica/ESTs/; EBI-ENA archive
ERP000012: an initial characterization of the F. hepatica
transcriptome using 454-FLX sequencing). Transcripts and
ESTs that matched at least one of the already known FABPs in a
BLAST analysis were included in alignments. From the
alignment a phylogenetic tree was constructed in MEGA v 4.0
using a neighbor-joining method, 1000-replicate, bootstrapped
tree. The amino acid data were corrected for a gamma
distribution (level set at 1.0) and with a Poisson correction.
Bioinformatics: Analysis of Novel FABPs
Secondary structure analysis of novel FABP isoforms was
conducted using PSIPRED available at http://bioinf.cs.ucl.ac.
uk/psipred/. Motif analysis was conducted using InterPro40 and
phosphorylation predictions using NetPhos 2.0.41 Sequences
from F. hepatica and F. gigantica encoding novel FABP isoforms
were also subjected to epitope predictions using a Kolaskar and
Tongaonkar Antigenicity prediction method,42 available at
http://tools.immuneepitope.org/tools/bcell/iedb_input, and
signal peptide analysis using the Signal P 4.1 server and a cutoﬀ
point of 0.45.43 Intron−exon structures of novel F. hepatica
FABP isoforms were also determined using Artemis44 on
sequences identiﬁed in the F. hepatica genome.45
Cloning
Novel FABP isoforms from F. hepatica and F. gigantica were
cloned using primers designed on F. hepatica and F. gigantica
transcripts (FABP IV: forward primer 5′ ATG GAA GCA TTC
GTC GGA 3′ and reverse primer 5′ TCA AAT TTT CTG GAA
TTT GAA G 3′. FABP V: forward primer 5′ CGG GTC TCT
GCCCTGTAT ATT 3′ and reverse primer 5′ TGTGACGGG
ATA AAC CCA AT 3′. FABP VI: forward primer 5′ TCG CCA
TAT TGG TAC ATT 3′ and reverse primer 5′ CAT TTA ATG
GGC GCC GCT 3′. FABP VII: forward primer 5′ TCA ACC
ATG TCA AAG CTT AT 3′ and reverse primer 5′ GAC AAG
CGG GTA CAT TCA TG 3′ or 5′ GAC AAG CTT GTA CAT
TCA TG 3′). Fasciola FABP sequences were ampliﬁed using
PCR. Both F. hepatica and F. gigantica sequences were then
cloned into the pGEM-T easy vector (Promega) according to
manufacturer’s instructions, screened and sequenced in-house.
Recombinant Protein Production and Puriﬁcation
FABP IV and V from both fasciolids were ampliﬁed from
plasmids containing inserts with the addition of Nde-I and Not-I
restriction enzyme sites for directional cloning into the pET28a
(Novagen) expression vector. Recombinant FABP protein was
expressed via the Escherichia coli BL21(DE3) and pET28a
expression vector system (Novagen) and puriﬁed using nickel-
aﬃnity via a C-terminal polyhistadine tag as previously
described.31 Purity was assessed by ESI mass spectrometry and
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE).
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■ RESULTS
Characterization of FABP from F. hepatica Ontogeny
To eﬀectively resolve the known FABP isoforms present in F.
hepatica, we subjected both adult and newly excysted juveniles
(NEJs) to preliminary 2D SDS-PAGE analysis using broad-range
IPG strips to localize FABP representatives. On the basis of
previous 2D SDS-PAGE investigations into the FABP super-
family of Fasciola,15,19,36 the comparison of NEJ and adult 2D
arrays revealed a dramatic reduction of FABP isoforms in NEJs
(Figure 1a). This absence of FABPs from the NEJ proteome
included the slightly acidic FABPs, isoforms I and II (Figure 1a
(i)), and the basic isoform, FABP III (Figure 1a (ii)). As a result
of these preliminary proteomes, further FABP isoform
delineation was to be conducted upon adult samples using
selective IPG strips (pH 4.7 to 5.9 for acidic FABPs and pH 7−10
for basic FABPs) to provide maximum resolution.
FABP Subproteome of Adult F. hepatica
Separation of adult F. hepatica somatic homogenates on narrow
and micro range IPG strips and subsequent SDS-PAGE resulted
in identiﬁcation of FABP isoforms belonging to the type I, II, and
III subfamilies. A total of 15 protein spots were consistently
identiﬁed via Progenesis analysis lying below the 20 kDa marker
and occupying the recognized FABP “zones” (Figure 1b). MSMS
data from the peptides excised from 4.7 to 5.9 micro range gels
(Figure 1c) conﬁrmed that FABP II isoforms appear in four
diﬀerent locations on the gel, varying in pI as well as in molecular
weight (Table 1). FABP I (Fh15) isoform was found in three
locations of the same gel analysis. A discrepancy in pI and
molecular weight between values calculated by Progenesis (5.3-
5.6/17.4-20.5 kDa) and those predicted from Genbank entries
(5.93/14936.04 Da for FABPII, Q7M4G1 and 5.91/14712.08
Da for Fh15, Q7M4GO) was observed. To account for multiple
FABP locations, we investigated potential sites of post-
translational phosphorylation and identiﬁed ﬁve serine and
threonine residues for FABP I (Fh15) and three for FABP II
predicted with high signiﬁcance to be phosphorylated.
MSMS data from the peptides excised from pH 7−10 narrow
range gels (Figure 1d) conﬁrmed that FABP III is the most
abundant FABP isoform and was identiﬁed in ﬁve diﬀerent
locations on the gel, varying principally in pI (Table 1). FABP II
was identiﬁed in two further locations and in both cases
colocalized with FABP III. Of interest was the solitary
identiﬁcation of FABP III colocalized with a serine/threonine
protein kinase. As with FABP I and II, FABP III potential sites of
post-translational phosphorylation were investigated, identifying
three serine and one threonine residues predicted with high
signiﬁcance to be phosphorylated. Only two protein spots
identiﬁed did not contain FABP isoforms.
Figure 1. Representative global protein arrays of F. hepatica FABPs. F. hepatica ontogeny 2D SDS-PAGE protein arrays of (a) newly excysted juvenile
and (b) adult F. hepatica. Circled areas within the arrays localize known FABP isoforms I, II, and III. Therefore, narrow range (pH 7−10) andmicrorange
(pH 4.7 to 5.9) IPG strips were chosen as the most suitable range to eﬀectively resolve the F. hepatica FABP members (denoted by dashed lines). Both
arrays were loaded with 250 μg of cytosolic protein and run on linear pH 3−10 IPG strips and on 14% acrylamide SDS-PAGE. Both arrays were
Coomassie blue stained. (c) Representative microrange (pH 4.7 to 5.9) and (d) narrow range (pH 7−10) protein arrays of adult F. hepatica somatic
samples for FABP location and identiﬁcation. Both panels c and d were loaded with 1 mg of cytosolic protein, run on 14% acrylamide SDS-PAGE, and
Coomassie blue stained. Circled spots correspond to those proteins consistently present on averaged gels, and their putative protein identiﬁcations can
be found in Table 1.
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Potential Immune Recognition of FABP Isoforms
Having identiﬁed the isoforms of FABP present in adult F.
hepatica, somatic homogenate samples were then subjected to
1D Western blotting using a pooled bovine infection sera time
course to reveal the dynamics of the FABP superfamily members
and the host IgG response. Somatic homogenate samples were
probed with time-course sera fromweek 0, naiv̈e animals, to week
14 post-infection (excluding week 10 post-infection) to look for
Figure 2. Phylogenetic analysis of vertebrate and Fasciola FABPs to determine the clade structure of FABP isoforms present in F. hepatica and F.
gigantica. Neighbor-joining phylogenetic tree constructed using amino acid sequences through MEGA v 4.0 with 1000 bootstrapped support and a
Poisson correction. All reported accession numbers are from Genbank. Where sequences were identiﬁed in silico, only contig numbers are reported.
Those from F. giganticawere taken from the study of Young et al.39 and those from F. hepatica were taken from Young et al.39 or transcripts produced by
the University of Liverpool (EBI-ENA archive ERP000012: an initial characterization of the F. hepatica transcriptome using 454-FLX sequencing).
Sequences from F. gigantica NEJs were sequenced in house.
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FABP interaction. Data showed that an IgG response to proteins
of the appropriate sizes could be observed from as early as 2
weeks post-infection (Figure S1A), with two bands visualized.
The extent of this IgG recognition persisted until 14 weeks post-
infection. To determine if any of the FABP isoforms (FABP I, II,
or III) were responsible for the IgG recognition, we subjected all
samples to 2DE proﬁling, as described previously followed by
Western blotting.
The 2DE array, spanning pH 4.7 to 5.9, of the cytosolic
fraction of adult liver ﬂuke homogenate was transferred to NC
membranes and assayed with sera from infected and naiv̈e cattle.
Pooled sera from week-8 post-infection produced the strongest
IgG response and thus selected to probe 2DE Western blot
arrays. The transfer of somatic samples to membranes for
antibody testing was assessed using amido black staining (Figure
S1b). Once probed with week 8 sera only very weak IgG
Figure 3.Characterization of novel FABP isoforms. (A) Bioinformatic characterization of F. hepatica fatty-acid-binding protein gene structures. All three
currently identiﬁed FABP isoforms (I, II, and III) were identiﬁed within the F. hepatica genome45 and their intron-exon structures identiﬁed. These were
with those of the four novel FABP isoforms (IV, V, VI, and VII). Exons shaded in gray indicate deviation from those structures identiﬁed within isoforms
I, II, and III. Reported exon sizes are in nucleotide bp. (B) Fatty-acid-binding protein secondary structure prediction. A multiple alignment of all four
novel FABP isoforms from both F. hepatica and F. gigantica was subjected to secondary protein structure prediction to identify the FABP characteristic
structure containing 10 β-strands and 2 α-helices. Predictions were carried out using PsiPred Version 3.2.68 Each β-strand or α-helix is boxed and
numbered. The extended C-terminal of isoforms VI and VII is apparent with additional β-strand or α-helix predictions shown in gray shaded dashed
boxes or open dashed boxes, respectively. The three domains that constitute the lipocalin-binding domain are boxed in blue. Arrowed are the starting
and ending residues of the IPR000463 cytosolic fatty-acid-binding domain signature within domain 1. The GXW triplet domain in domain 1 is
underlined in green. All predicted phosphorylation sites (S, T, and Y) are boxed in red.
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responses were seen. This recognition was primarily to spots
containing FABP I (Figure S1c, spots 2, 4, and 5 in Figure 1c) and
extremely weakly to those spots containing FABP II (Figure S1c,
spots 6−8 in Figure 1c). Importantly, the strongest, albeit weak,
IgG response was to spot 2, which contained both FABP I and a
translation initiation inhibitor (Figure S1c, spot 2 in Figure 1c).
Thus, it is likely that the immune recognition of FABPs I−III is
extremely low. Importantly, naiv̈e sera (week 0) showed no IgG
response (Figure S1d). IgG responses were also highlighted in an
unresolved section of the gel at the pI 5.9 side of the gel.
The 2-DE array (pH 7−10) of the cytosolic fraction of adult
liver ﬂuke homogenate was transferred to NC membranes and
assayed with sera from infected and naiv̈e cattle. As with acid
FABP isoforms, week-8 infection sera was chosen to screen the
basic putative FABPs for immunoreactivity. However, no
antibody recognition could be detected for any of the basic
FABP isoforms or indeed any proteins lower than the 30 kDa
marker (Data not shown).
Transcript and Phylogenetic Analysis of FABP Isoforms
Available transcript and EST data sets from both F. hepatica and
F. gigantica and the F. hepatica genome were searched for
representative FABP superfamily members. All identiﬁed
members representing known FABP isoforms I, II, and III and
potential new FABP isoforms were aligned with members of the
known vertebrate FABP classes. From the multiple alignment a
phylogenetic tree was constructed to ascertain the Fasciola FABP
clade structure. The previously identiﬁed Fasciola FABP I, II, and
III clades were well-conserved and most related to clades from
the known vertebrate Heart (H, B, A, T, and M-FABP) and
Intestinal (I and K-FABP) FABP groups (Figure 2). The FABP
type I clade comprises the recombinant FABP I (Fh15) from F.
hepatica and reveals a clear separation between representatives of
both Fasciola species into two subclades. This subclade structure
is not replicated in clades II or III because there is a lack of F.
gigantica FABP II representatives, and the sequences of FABP III
from both species are 100% identical at the amino acid level. A
fourth novel clade (Bootstrap support 90%), termed FABP V,
clustered near the known three isoforms but much closer to the
known vertebrate classes, in particular, the vertebrate keratino-
cyte and intestinal FABP isoforms. Interestingly, the FABP Sm14
from S. mansoni clustered close to Fasciola FABP clade V. Three
further novel clades of Fasciola FABPs were identiﬁed with
strong bootstrap support, termed FABP IV (99%), VI (91%),
and VII (96%; Figure 2). All three of these putative novel FABP
clades, as with FABP clade I, also showed a distinct separation
between representatives of F. hepatica and F. gigantica. Both
FABP clades VI and VII were most related to the vertebrate liver
and ileal forms of vertebrate FABPs with FABP clade IV to a
lesser extent.
Representatives of the novel four FABP clades from both F.
hepatica and F. gigantica were cloned and sequenced. This
revealed proteins of 132 (FABP IV), 134 (FABP V), 162 (FABP
VI), and 166 (FABP VII) amino acids in length. The average
amino acid sequence similarity to the previously identiﬁed
Fasciola FABPs ranged from as low as 22 to 48%. Speciﬁcally,
FABP IV was most similar to FABP I (24 to 25%), FABP V to
FABP III (48%), FABP VI to FABP II (24 to 25%), and FABP
VII to FABP III (22%). Initially, all sequencing was performed on
adult cDNA however expression of all four novel FABPs was
conﬁrmed in NEJ cDNA (data not shown). All F. hepatica and F.
gigantica clones for the novel FABP classes are included in Figure
2.
Conﬁrmation of Novel FABP Isoforms
All four newly identiﬁed putative FABP sequences were
conﬁrmed as FABPs using bioinformatics. As an initial
comparison, the gene structures of the four new isoforms were
compared with those of FABPs I, II, and III (Figure 3A). This
analysis revealed that only the structure of FABP IV matched
those of I−III. FABPV diﬀered by only 6 bp (3 bp in exon 2 and 3
bp in exon 4). Of note was the dramatic increase in size of exon 4
in both FABP VI and VII.
All novel FABP isoforms were then subjected to secondary
structure prediction analysis to identify the characteristic ten
antiparallel β-strands comprising a β-barrel and the helix-turn-
helix cap. All novel FABP isoforms from both F. hepatica and F.
gigantica were predicted to have the FABP characteristic
structure (10 β-strands and 2 α-helices; Figure 3B). All four
novel isoforms were also subjected to InterPro sequence analysis
for FABP domain predictions. In all cases, both IPR011038
Calycin-like and IPR012674 Calycin were predicted for both
Table 2. Fatty-Acid-Binding Signature of Novel Fatty-Acid-Binding Proteinsa
signature requirement
+ − + + − + + + + + − − +
sequence GSAIVK FE FYW X LIVMF X X K X NHG FY DE X LIVMFY LIVM N G LIVMAKR
% motif
match
Fhep
FABPIV
G K W K L D S Y E N V D A I L N M L 88.9
Fgig
FABPIV
G K W K L D S Y E N V D A I L N M L 88.9
Fhep
FABP V
G K W K L V D S R D F D K V M V E L 94.4
Fgig
FABP V
G K W K L V D S R D F D K V M V E L 94.4
Fhep
FABPVI
G E W E A T G H R N F S S I L A E I 83.3
Fgig
FABPVI
G E W E A T G Q E N F S S I L A E I 83.3
Fhep
FABPVII
G E W K C V E C S N L E P V M I E I 83.3
Fgig
FABPVII
G E W K C V E C S N L E P V L I E V 83.3
aFatty-acid-binding signatures of all four novel FABPs from both F. hepatica and F. gigantica are highly conserved, especially for FABP V. Residues in
bold show 100 suitability to the signature requirements. A percentage match is given for the 18 residue motif.
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Fasciola species isoforms. Furthermore, three of the four isoforms
(excluding FABP IV) were predicted to have IPR000463
cytosolic fatty-acid-binding properties. Of note was a well-
conserved cytosolic fatty-acid-binding signature in all novel
FABP isoforms, in particular FABP V with 94.4% sequence
identity to the recognized motif signature (Table 2; GKWKLV-
DSRDFDKVMVEL). All four novel sequences were also
subjected to a SVMProt prediction to identify functional
characterization. Novel FABPs were all identiﬁed as lipid-binding
proteins, further conﬁrming their status as FABPs, with the
exception of FABP VI. In this instance, FABP VI was identiﬁed as
a zinc-binding protein. As expected, all novel FABP isoforms
lacked a signal peptide, further conﬁrming them as cytosolic
FABP isoforms. Importantly, both N-terminal residues G6 and
W8 are conserved in all novel FABP isoforms.
Expression of FABP Isoforms IV and V
Because of their similarity to the three previously known FABP
isoforms, both FABP IV and V from F. hepatica and F. gigantica
were chosen for expression in E. coli for immunological
characterization. Both proteins from both species were puriﬁed
using Ni2+ aﬃnity chromatography and assessed for purity using
1D and 2D SDS-PAGE in conjunction with ESI−MS for an
accurate mass assessment. All proteins were puriﬁed to a high
level, as assessed by both methods (Figure 4). Both FABP IV
(predicted molecular weight 15 073 Da and 16 351 Da with the
Histag) and V (predicted molecular weight 15 372 Da and 16
650 Da with the Histag) had commonly observed Na+ adduct
formation (mass shifts of 22 Da between peaks) and a shift of 63
Da from the expected molecular weight relating to ammonium
formate (NCOONH4) adduct formation during ESI−MS
analysis (Figure 4a). FABP V was observed as a more basic
isoform from 2D SDS-PAGE (approximate pI 8.4; Figure 4c)
than that of FBAP IV (Figure 4b). Minor shifts from the
predicted molecular weights were seen for both isoforms, which
may indicate lipid binding during puriﬁcation as no delipidation
steps were incorporated.
Both expressed FABP isoforms were assessed for serum
antibody responses using a time course of Fasciola-hepatica-
challenged and naiv̈e bovine sera (weeks 0−14 post infection).
FABP IV showed no IgM or IgG responses throughout a 14-
week infection (data not shown). However, FABPV from both F.
hepatica and F. gigantica had observable IgM and IgG responses,
as assessed by Western blotting (Figure 5). IgM responses
toward FABP V were visualized strongly at week 4−6, whereas
IgG responses were visualized earlier at weeks 2−4.
A total of 41 Fasciola individuals were subjected to an analysis
of FABP V to identify any potential sequence variation within the
population (data not shown). This included 33 adult F. hepatica
from three diﬀerent populations (South Gloucester, Camarthen
and Llanidloes; all U.K.) and eight adult F. gigantica (North and
South India). Upon analysis, only a few single amino acid
polymorphisms (SAAPs) were identiﬁed between all Fasciola
spp. FABP V sequences. This was limited to just four of the
individuals sequenced with a total of four SAAP sites. A single
SAAP site was localized in two individual F. hepatica from the
Llanidloes population (Q66L and Y130N), a further SAAP was
identiﬁed in a Northern India F. gigantica sample (Q66R), and
ﬁnally two SAAPs in one F. gigantica sequence from the South of
India (V69I and K87R). Interestingly, three of the ﬁve SAAPs
identiﬁed (those at sites 66 and 69) fall within a predicted
epitope that spans amino acid residues 63−70.
Figure 4. Expression of recombinant protein forms of novel FABP isoforms. (a) Puriﬁcation of FABP IV from F. hepatica with purity revealed via ESI
mass spectrum of the Ni2+ aﬃnity puriﬁed rFhFABP IV showing the molecular weight at 16287.7 ± 0.49 Da (with six sodium adduct peaks). Data for
FABP V not shown. (b) Purity was also assessed with a 2D SDS-PAGE protein array run on 14% SDS-PAGE and Coomassie blue stained. (c)
Puriﬁcation of FABP V from F. hepatica assessed with a 2D SDS-PAGE protein array run on 14% SDS-PAGE and Coomassie blue stained.
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Absence of Novel FABP Isoforms in Exosome-Like Vesicles
Because both FABP II and III have been previously identiﬁed in
F. hepatica exosome-like vesicles24 proteomic data were searched
for all novel FABP isoforms. Interestingly, none of the novel
FABP isoforms were identiﬁed in exosome-like vesicles (personal
communication, Marcilla, June 2014).
■ DISCUSSION
Reductionist studies have proposed diverse roles in parasitism for
FABP isoforms, including uptake/transport of fatty acids (FAs),
as there is limited synthesis in helminth worms, immune
modulation via their fatty acid ligands, and the sequestration of
anthelmintics as a resistance mechanism. However, to eﬀectively
investigate the function of the FABPs, it is imperative to ﬁrst
resolve and fully delineate the complexity and novelty within the
superfamily. Hence, we have utilized a polyomics approach
incorporating genomics, transcriptomics, and proteomics to
reveal an FABP superfamily from the pathogenic liver ﬂuke
parasite F. hepatica with seven distinct isoforms, four more than
previously discovered.
Our previous observations revealed a dominance of FABP
abundance in adult liver ﬂuke rather than the more pathogenic
NEJs, where FABPs were signiﬁcantly reduced in abundance.
Relatively low levels of FABPs in juvenile liver ﬂuke compared
with adults is replicated in other parasitic platyhelminths and
thus is not simply related to adult survival in the liver/bile
environment. For example, in schistosomes, an increase in
FABPs is observed from newly developed schistosomula through
lung-stage schistosomula and with the greatest abundance of
FABPs found in adults,46,47 suggesting that FABPs are important
for development. The diﬀerential expression of FABPs from F.
hepatica may be explained by functional roles, namely,
intracellular transport and detoxiﬁcation. Intracellular FABPs
function as FA transport proteins.16,18 Therefore, in the absence
of FA synthesis in adult parasitic ﬂatworms, high levels of FABPs
may transport FAs that are taken up via uncharacterized
tegumental mechanisms from the host environment.48 However,
within NEJs there is a high level of preformed/stored lipid to
support initial host survival49,50 and likely a reduced requirement
for FA uptake and FABP transporters and hence their dramatic
reduction observed in 2DE arrays (Figure 1A). The greater
abundance of adult liver ﬂuke FABPs may be related to adult
feeding patterns. At the onset of blood feeding it has been
suggested that FABPs are essential for the uptake of FAs from
host blood.51 Furthermore, FABPs sequestrate and remove
haem, a toxic byproduct of blood feeding responsible for
hydrogen peroxide (H2O2) production if in the free form.
52 In
support of this theory, antibodies directed toward F. hepatica
FABPs can be observed around 2−4 weeks post-infection (ref 53
and the present study) coinciding with migration through the
liver and the onset of blood feeding behavior.
Delineating the adult FABP proteome revealed the three
known Fasciola FABP isoforms, reported in the recent
publication of the F. hepatica genome,45 in multiple locations
within the 2DE arrays (three locations for FABP I, six for FABP
II, and ﬁve5 for FABP III), an observation often causing
confusion over true isoform identiﬁcation.54 So why are the F.
hepatica FABP isoforms resolving into numerous protein spots,
and will this impact upon future diagnostics or vaccines?Multiple
resolved versions of FABP isoforms have been attributed to post-
translational modiﬁcation, especially phosphorylation,55 and
tyrosine phosphorylation is known to inhibit/modulate the
binding of FAs.56 In mammals, phosphorylation of FABPs
appears low, >1%,54 but bioinformatics predicts multiple
phosphorylation sites in Fasciola FABPs, tentatively suggesting
a diﬀerence in FA transport regulation between host and parasite.
In contrast, multiple resolved versions of FABP isoforms could
also be attributable to irreversible ligand or FA binding.54
Resolving the function of each FABP isoform is compounded
by the complex diversity, tissue, and temporal speciﬁcity and
ligand preferences of each FABP isoform.16 For example,
FgFABP I and FgFABP III from F. gigantica have some
overlapping roles, yet FgFABP I supports the male reproductive
system, and FgFABP III supports the female reproductive
system.57 It is likely that this distribution of FABPs I and III will
be replicated within F. hepatica tissues. In the current study, F.
hepatica FABP isoforms I−III were assessed for host immune
recognition. Mirroring the study of Chunchob et al.,57 no
immune recognition was observed to FABP isoform III using
bovine sera. However, recognition of a protein spot containing
FABP isoform I was seen, unlike for FgFABP I. However, the
strongest, albeit weak, immune recognition identiﬁed was to a
protein spot containing both FhFABP I and translation initiation
inhibitor (TII). Given the lack of immune recognition to other
FhFABP I protein spots in the array, the primary response seen
may relate to TII. This is especially pertinent with the
identiﬁcation of TII in F. hepatica tegument preparations, both
S2SS and UTCS fractions, of the study by Wilson et al.,20 and in
surface preparations, both SPF and IPF protein fractions, from
the study of Harcariz et al.58 It is likely that TII is exposed to the
Figure 5. Antibody responses to novel Fasciola FABP isoform V.
Representative Western blots of rFhFABP V samples looking for both
IgM and IgG responses rFhFABP V were run on 14% acrylamide SDS-
PAGE, electro-transferred to membranes, and Western blotted with
pooled bovine infection sera from week 0, naiv̈e sera, to week 14 post-
infection as the primary antibody with antibovine IgM (a) or antibovine
IgG (b) as the secondary antibody. A F. hepatica somatic sample (S) was
also included and as a positive control using sera from week 8 post-
infection. White arrows indicate the start of immune recognition. Black
arrow highlights the F. hepatica cathepsin L proteases recognized by
bovine IgG.36
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host immune system and thus elicit the immune response
identiﬁed in the current study.
We performed a bioinformatic analysis of currently available
transcript and genomic databases for F. hepatica and F. gigantica
to probe for the ﬁrst time the complexity of the liver ﬂuke FABP
superfamily. As with previous phylogenetic studies, FABP
isoforms I, II, and III formed a distinct group close to the
vertebrate H- and I-FABP groups. FABP I isoforms had a clear
separation related to Fasciola species not seen in FABP II or
FABP III isoform groupings due to limited sequence data
availability and 100% amino acid sequence identity between
fasciolids, respectively.
Further phylogenetic analysis identiﬁed four new FABP
isoforms represented in both F. hepatica and F. gigantica and in
both adults and NEJs, namely, isoforms IV−VII. All four of these
novel isoforms were conﬁrmed as FABPs using bioinformatics.
Only FABP isoform VI did not conform to every bioinformatics
analysis predicting an FABP; namely, a SVMProt prediction did
not identify FABP VI as a lipid-binding protein, predicting a zinc-
binding protein instead. In this case, FABP VI was classiﬁed as an
FABP on its gene structure (exons 1−3 matching known FABP
exon structures), protein structure (10 β-strands and 2 α-
helices), and its highly conserved cytosolic FA-binding domain
signature (88.9% amino acid identity). Phylogenetically, iso-
forms IV, VI, and VII were split between F. hepatica and F.
gigantica, as seen with isoform I. Using bioinformatic analysis, all
novel sequences were conﬁrmed as authentic FABP isoforms by
analyzing gene structures, sequence motifs, and secondary
structure prediction.
FABP isoform V was closely related to isoforms I−III but
closer to vertebrate I- and K-FABPs. Vertebrate I-FABPs are
generally known to bind FAs only rather than additional ligands.
In addition, FAs bound to I-FABPs are also bound in a diﬀerent
conformation to the other vertebrate FABPs (FAs bind to I-
FABPs in a bent conformation instead of a U-shaped
conformation when bound to alternative vertebrate FABPs).59
Therefore, it is possible that FABP V is expressed speciﬁcally for
the uptake of FAs from the host, although binding similarities to
I-FABPs will require conﬁrmation as the ligand-binding residues
of I-FABP (Y70, L72, A73, W82, Q115 and Y117) are not
conserved in FABP isoform V.59
The three other novel Fasciola FABP isoforms, IV, VI, and VII,
clustered away from the previously known Fasciola FABPs and
were located close to the vertebrate L- and IL-FABP groups. As
with the FABP I, II, and III isoforms, we would expect to identify
multiple versions upon a 2DE array. The potential of cysteine
modiﬁcation via glutathionylation or cysteinylation, related to
the redox state of the host liver, may complicate distinguishing
true FABP isoforms, as seen for vertebrate L-FABP.54 Vertebrate
L-FABPs are distinctly diﬀerent from other vertebrate FABP
groups. First, they diﬀer in the FA uptake mechanism, which in L-
FABPs occurs via diﬀusion16 rather than collision, as
demonstrated for H- and I-FABPs. Furthermore, as a result of
their large binding pocket, ligands of L-FABPs bind at a 2:1 molar
stoichiometry ratio as opposed to 1:1 in all others examined.60
Importantly, vertebrate L- and IL-FABPs are capable of binding
FAs as well as bulky ligands such as bile salts, cholesterol, and
haem.61 While all of these abilities remain to be conﬁrmed in the
novel Fasciola FABP isoforms IV, VI, and VII, it would seem
logical that these isoforms could well be adapted for a “life in bile”
as a blood feeder. Interestingly, two of the novel FABP isoforms,
VI and VII, had a 31 and 33 amino acid C-terminal extension,
respectively. While the role of these extensions is currently
unknown, they may well be involved in interactions or
attachments to other proteins or for membrane association.62
It has been suggested that a reduced diversity of FABP
isoforms in invertebrates compared with vertebrates represents a
lower speciﬁcity for ligands but a larger repertoire of interactions
within the cell.16 In contrast, the number of FABP isoforms in
Fasciolids has expanded, suggesting potential specialization of
FABP isoforms. The vertebrate groupings H-, I-, and L-FABPs
reﬂect their speciﬁc binding abilities.61 Thus, it is likely that
Fasciola FABPs may also segregate according to their binding
abilities. The separation of FABP isoforms I, II, III, and V from
isoforms IV, VI, and VII may represent two clusters based on
their respective binding capabilities.
Disappointingly, none of the newly recognized FABP isoforms
(IV−VII) were identiﬁed during proteomic analysis. This could
potentially result from the quantity of protein in the identiﬁed
protein spots, identiﬁed as FABPs I, II, and III, suppressing any
recognition of the novel FABP isoforms. Alternatively, it may be
that FABPs IV−VII may be of more importance in the juvenile
stages of the parasite; such is the case with cathepsin proteases
(cathepsin L1, 2, and 5 in adults, whereas cathepsin L3 and 4 with
cathepsin B in juveniles).27
FABP isoforms IV and V were expressed as recombinant forms
to further understand the immune responses directed to the
FABP family for diagnostic or vaccine potential. Despite its
absence from F. hepatica exosome-like vesicles, FABP isoform V
shows potential as a diagnostic or vaccine candidate with strong
IgM and IgG responses seen in pooled bovine infection sera. As
diagnostics, Fasciola FABPs show promise with two studies by
Allam and colleagues, suggesting FABP for the diagnosis of F.
gigantica infections in both buﬀalo and man.63,64 In both cases
FABPs were puriﬁed from crude adult worm extracts, likely to
contain multiple FABP isoforms. Thus, FABP isoforms I−III are
likely to dominate the preparation, but the presence of FABP
IV−VII cannot be discounted. Furthermore, Hillyer et al.53 also
noted that antibodies to FABP I could also be observed at 2−4
weeks post-infection, highlighting the excellent potential of
FABPs as diagnostics. However, to further improve diagnostic
potential, the correct choice of which FABP isoform to target is
essential. For example, from the evidence presented in the
current study, poor recognition to FABP I−III in natural
infections and strong IgM and IgG responses to FABP V from
weeks 2−4 FABP isoform V may be a potential choice as a
diagnostic. However, with the expanded FABP family, from three
to seven members, each isoform must be investigated speciﬁcally
to gauge the best choice for a diagnostic.
As vaccine candidates, FABPs have also been studied in depth.
Early studies using FhFABPs looked promising, with trials in
mice revealing 69−78% protection. Unfortunately, these
protection rates did not translate well into cattle trials with two
studies giving 31 and 55% protection (vaccine trials reviewed by
ref 65). Poor translation into target animals was also observed in
trials for protection against F. gigantica. For example, in buﬀalo, a
35.8% reduction in worm burdens with associated reductions in
liver enzymes (AST) was observed.66 However, this trial also
demonstrated a high antifecundity eﬀect.66 As with other
candidate vaccines based on protein superfamilies, the choice
of which isoform to vaccinate with is key decision ensuring
plasticity of the target is low.27 Therefore, Fasciola FABP isoform
V may be a strong candidate for novel vaccine trials, perhaps as
part of a combination therapy. A potential combination therapy
could incorporate FABP V and an immune suppressor
component, such as FhGST-S1.19,67 FABP potential could also
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be enhanced by conducting similarity studies between those
isoforms eliciting an immune response (FABP isoforms I, II, and
V), whichmay reveal the structural details that are responsible for
triggering this immune response in the host organism. This could
lead to the rational design of protein complexes that may prove to
be more eﬀective in vaccine trials than current vaccine
candidates.
■ CONCLUSIONS
A polyomics approach has successfully revealed the cytosolic
FABP superfamily complement expressed in F. hepatica adults.
These have been classiﬁed into seven isoforms, types I−VII, with
a potential clustering of isoforms into two groups: group one
consisting of isoforms I, II, III, and V and group two consisting of
isoforms IV, VI, and VII. These two groupings may reﬂect their
binding dynamics. Importantly, FABP isoform V from both F.
hepatica and F. gigantica shows promise as a new diagnostic
antigen or as a vaccine candidate.
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